ARTICLE | Strategy
Vertical vision
How Shire’s Parion deal adds to its ophthalmics pipeline
May 12, 2017 9:45 PM UTC
Shire plc’s deal with Parion Sciences Inc. is a step toward building vertically in ophthalmics, much like it has done in hereditary angioedema and hemophilia.
On May 1, Shire gained exclusive, worldwide rights to P-321 ophthalmic solution, an epithelial sodium channel (ENaC) inhibitor in development to treat dry eye disease...